In contrast , at weeks 6 and 12 , the mean symptom-scale scores for trametinib decreased from baseline ( symptoms improved ) for pain ( 11-12 points ) , insomnia ( 10-12 points ) , and appetite loss ( 1-5 points ) , whereas those for diarrhea worsened ( 15-16 points ) .